Dorothy Bishop is a psychologist at the University of Oxford, where she heads an ERC-funded programme of research into cerebral lateralisation for language. She is a supernumerary fellow of St John’s College Oxford, a Fellow of the Royal Society, Fellow of the British Academy and Fellow of the Academy of Medical Sciences. Her main research interests are in the nature and causes of developmental language difficulties, with a particular focus on psycholinguistics, neurobiology and genetics. She has a popular blog, Bishopblog, which features posts on a wide range of topics, including those relevant to reproducibility. She is also on Twitter as @deevybee.
Matthias Egger studied at the University of Bern and was awarded a British Council fellowship in 1986 to study epidemiology at the London School of Hygiene & Tropical Medicine (LSHTM). In the 1990s, at University College London, he became involved in the Swiss HIV Cohort Study. Today, Egger helps run the International Epidemiology Database to Evaluate AIDS (IeDEA). Egger is Professor of Epidemiology and Public Health at the University of Bern, as well as Professor of Clinical Epidemiology at the University of Bristol, UK. Between 2002 and 2017, Egger was chair of the Institute of Social and Preventive Medicine (ISPM) at the University of Bern. Matthias Egger is a member of several faculties and international scientific committees and a seasoned expert in higher education and research policy. He was elected as president of the National Research Council of the Swiss National Science Foundation in September 2016.
At the Charité Universitätsmedizin Berlin Ulrich Dirnagl is Professor for Clinical Neurosciences and serves as Director of the Department of Experimental Neurology. Since 2017 he is also the founding director of the QUEST Center for Transforming Biomedical Research at the Berlin Institute of Health. QUEST aims at overcoming the roadblocks in translational medicine by increasing the value and impact of biomedical research through maximizing the quality, reproducibility, generalizability, and validity of research. In preclinical as well as in clinical studies Ulrich Dirnagl’s research has revealed pathobiology which impact on the outcome after a stroke. Several of these mechanism can be therapeutically targeted, clinical trials are under way. In addition, through meta-research he was able to identify opportunities for improving research practice and to obtain evidence for the impact of interventions targeted to increase the value of biomedical research.
Stan Lazic is Co-founder and Chief Scientific Officer at Prioris.ai Inc.
and was formerly Associate Director in Statistics and Machine Learning at
AstraZeneca. His Research interests include the design and analysis of
biological experiments, improving the reproducibility of biomedical
research, and novel applications of Bayesian methods. He has a PhD in
neuroscience and a Masters in computational biology from the University of
Cambridge and is author of "Experimental Design for Laboratory Biologists:
Maximising Information and Improving Reproducibility", published by
Cambridge University Press.
Prof John Climax co-founded the Nasdaq listed Clinical Research Organisation, ICON plc in 1990, where he served for 19 years as CEO and Executive Chairman. He is currently a non-executive director on its board. In 2004 Prof Climax founded HDF a Swiss charity focused on violence against children. He was also a founding director of Science Gallery Dublin 2008 and Science Gallery International 2012. Prof Climax went on to establish two biotech companies - DS Biopharma in 2010, specialising in dermatology and Afimmune in 2016, focusing on fibrotic diseases. He is Adjunct Professor of Pharmaceutics at Royal College of Surgeons Ireland, Honorary Joint Professor of Clinical Pharmacology and Pharmacy at National University of Singapore and recently established a Chair in Clinical Therapeutics at University of Oxford.